Barr Pharma Wins Right to Sell Generic Fentora in 2018

Cephalon has agreed to drop a patent suit against Barr Pharmaceuticals, allowing the company to market generic Fentora in the U.S. in 2018, a year before the disputed patents expire. The company granted Barr a nonexclusive right to sell a generic of the pain drug Fentora (fentanyl citrate) beginning in October 2018, Cephalon says in an SEC filing.
Generic Line